Search Results - "Moritz, Berta"

Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice by Wilhelm, Martin, Mueller, Lothar, Miller, M. Craig, Link, Karin, Holdenrieder, Stefan, Bertsch, Thomas, Kunzmann, Volker, Stoetzer, Oliver J, Suttmann, Ingo, Braess, Jan, Birkmann, Josef, Roessler, Max, Moritz, Berta, Kraff, Stefanie, Salamone, Salvatore J, Jaehde, Ulrich

“…Abstract Background Studies have demonstrated that body surface area-based dosing of chemotherapy drugs leads to significant individual exposure variability,…”
Get full text

Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring: A Pharmacokinetic-Pharmacodynamic Simulation Study by Joerger, Markus, Kraff, Stefanie, Huitema, Alwin D. R., Feiss, Gary, Moritz, Berta, Schellens, Jan H. M., Beijnen, Jos H., Jaehde, Ulrich

“…Background and Objective Severe neutropenia is the most frequent and important toxicity of 3-weekly paclitaxel and puts patients at substantial risk of…”
Get full text

Prospective, multi-center study of 5-fluorouracil (5-FU) therapeutic drug management (TDM) in metastatic colorectal cancer (mCRC) patients treated in routine clinical practice by Salamone, Salvatore J., Jaehde, Ulrich, Mueller, Lothar, Link, Karin, Holdenrieder, Stefan, Bertsch, Thomas, Ko, Yon-Dschun, Kunzmann, Volker, Suttmann, Ingo, Braess, Jan, Roessler, Max, Moritz, Berta, Kraff, Stefanie, Miller, Michael Craig, Wilhelm, Martin

“…Abstract only 650 Background: Studies have demonstrated that body surface area (BSA)-based dosing of chemotherapy drugs leads to significant individual…”
Get full text

Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs) by Von Pawel, Joachim, Tseng, Jennifer, Dediu, Mircea, Schumann, Christian, Moritz, Berta, Mendell-Harary, Jeanne, Jin, Xiaoping, Feng, Wenqin, Copigneaux, Catherine, Beckman, Robert A.

“…Abstract only…”
Get full text

A prospective, multi-center study of individualized, pharmacokinetically (PK)-guided dosing of 5-fluorouracil (5-FU) in metastatic colorectal cancer (mCRC) patients treated with weekly or biweekly 5-FU/oxaliplatin containing regimens by Kunzmann, Volker, Link, Karin, Miller, Michael Craig, Holdenrieder, Stefan, Bertsch, Thomas, Mueller, Lothar, Ko, Yon-Dschun, Stoetzer, Oliver J., Suttmann, Ingo, Braess, Jan, Jaehde, Ulrich, Roessler, Max, Moritz, Berta, Kraff, Stefanie, Fritsch, Achim, Salamone, Salvatore J., Wilhelm, Martin

“…Abstract only…”
Get full text

FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases - a CESAR phase II study including pharmacokinetic, biomarker, and imaging data by MROSS, Klaus, SCHEULEN, Max, STRUMBERG, Dirk, KUHLMANN, Jan, KANEFENDT, Friederike, SÖRGEL, Fritz, JAEHDE, Ulrich, BURKHOLDER, Iris, MORITZ, Berta, BÜCHERT, Martin

“…The aim of this study was the evaluation of pharmacokinetic parameters, biomarkers, clinical outcome, and imaging parameters in metastatic colorectal cancer…”
Get full text

Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study by de Kleijn, Ester D, de Groot, Ronald, Hack, C Erik, H. Mulder, Paul G, Engl, Werner, Moritz, Berta, Joosten, Koen F. M, Hazelzet, Jan A

“…BACKGROUNDMeningococcal septic shock in children results in high mortality and morbidity, and decreased protein C levels in these patients are associated with…”
Get full text

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced non-small cell lung cancer (NSCLC) patient by Joerger, Markus, Von Pawel, Joachim, Kraff, Stefanie, Fischer, Juergen R., Eberhardt, Wilfried, Gauler, Thomas Christoph, Mueller, Lothar, Reinmuth, Niels, Reck, Martin, Kimmich, Martin, Mayer, Frank, Kopp, Hans-Georg, Behringer, Dirk M., Ko, Yon-Dschun, Frueh, Martin, Hilger, Ralf A., Roessler, Max, Moritz, Berta, Jaehde, Ulrich

“…Abstract only…”
Get full text

Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV by Richly, Heike, Maute, Luise, Heil, Gerhard, Rüssel, Jörn, Jäger, Elke, Koeberle, Dieter, Fuxius, Stefan, Weigang-Koehler, Karin, Aulitzky, Walter, Woehrmann, Bernhard, Hartung, Gernot Georg, Moritz, Berta, Burkholder, Iris, Scheulen, Max E., Bergmann, Lothar

“…Abstract only 4035 Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumours, but PDAC is still associated with a poor…”
Get full text

Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring by Joerger, Markus, Kraff, Stefanie, Huitema, Alwin DR, Feiss, Gary, Moritz, Berta, Schellens, Jan HM, Beijnen, Jos H, Jaehde, Ulrich

“…Background and Objective: Severe neutropenia is the most frequent and important toxicity of 3-weekly paclitaxel and puts patients at substantial risk of…”
Get full text

Use of plasmas from donors under oral anticoagulant treatment for the expression of INR values by MORITZ, B, LANG, H

Get full text